Selling, General, and Administrative Costs: Viatris Inc. vs Grifols, S.A.

A Comparative Analysis of SG&A Expenses: Viatris Inc. vs Grifols, S.A.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Grifols, S.A. from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced Grifols, S.A. in SG&A spending, with a notable increase of over 210% from 2014 to 2023. In contrast, Grifols, S.A. saw a more modest rise of approximately 90% in the same timeframe.

Key Insights

• Viatris Inc.: The company's SG&A expenses surged, peaking in 2023 with a 210% increase from 2014, reflecting strategic investments in growth and expansion.
• Grifols, S.A.: While Grifols maintained a steady increase, their expenses grew by 90%, indicating a more conservative approach.

This financial trajectory highlights the contrasting strategies of these pharmaceutical giants, offering valuable insights for investors and industry analysts.